LLY

1,045.35

-1.18%↓

JNJ

205.34

-0.12%↓

ABBV

224.4

-0.21%↓

UNH

324.92

+0.43%↑

AZN

90.2

-0.31%↓

LLY

1,045.35

-1.18%↓

JNJ

205.34

-0.12%↓

ABBV

224.4

-0.21%↓

UNH

324.92

+0.43%↑

AZN

90.2

-0.31%↓

LLY

1,045.35

-1.18%↓

JNJ

205.34

-0.12%↓

ABBV

224.4

-0.21%↓

UNH

324.92

+0.43%↑

AZN

90.2

-0.31%↓

LLY

1,045.35

-1.18%↓

JNJ

205.34

-0.12%↓

ABBV

224.4

-0.21%↓

UNH

324.92

+0.43%↑

AZN

90.2

-0.31%↓

LLY

1,045.35

-1.18%↓

JNJ

205.34

-0.12%↓

ABBV

224.4

-0.21%↓

UNH

324.92

+0.43%↑

AZN

90.2

-0.31%↓

Inicio・Lista de Acciones・Cassava Sciences Inc

Cassava Sciences Inc

Cerrado

SectorSanidad

2.88 -4.64

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

2.88

Máximo

3.05

Métricas clave
By Trading Economics
Ingresos	33M -11M
Ventas	840K 840K
BPA	-0.22
Margen de beneficios	-1,286.548
Empleados	30
EBITDA	35M -11M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+164.03% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-4.3M 142M
Apertura anterior	7.52
Cierre anterior	2.88

Noticias sobre sentimiento de mercado

By Acuity

67%

33%

334 / 374 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bearish Evidence

1.56 / 1.7 Soporte y Resistencia

Cassava Sciences Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

1 dic 2025, 21:16 UTC

Adquisiciones, fusiones, absorciones

Marsh McLennan Agency Acquires Three Hawaii-Based Insurance Brokerages

1 dic 2025, 18:51 UTC

Principales Movimientos del Mercado

Shopify Stock Falls on Cyber Monday System Outages

1 dic 2025, 23:47 UTC

Charlas de Mercado

Nikkei May Rise on Bargain Hunting -- Market Talk

1 dic 2025, 23:27 UTC

Adquisiciones, fusiones, absorciones

Genting Bhd. Stake in Genting Malaysia Now at 73.13% Vs. 49.36% Ahead of Take Private Offer Made in October

1 dic 2025, 23:26 UTC

Adquisiciones, fusiones, absorciones

Genting Bhd.: Offer to Take Genting Malaysia Private Closed on Dec.1

1 dic 2025, 23:25 UTC

Adquisiciones, fusiones, absorciones

Bitcoin Rout Picks Up Steam as Investors Fret Over a New 'Crypto Winter' -- WSJ

1 dic 2025, 21:52 UTC

Adquisiciones, fusiones, absorciones

Wood Partners Announces Itochu Corp. Purchase of 19.5% of Wood Partners

1 dic 2025, 21:42 UTC

Adquisiciones, fusiones, absorciones

Goldman's Latest Acquisition Is a $2 Billion Bet on Active ETFs -- Barrons.com

1 dic 2025, 21:41 UTC

Charlas de Mercado

Canada's GDP Revisions Mean Lower Debt-to-GDP Ratio, Better Productivity -- Market Talk

1 dic 2025, 21:41 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

1 dic 2025, 21:41 UTC

Charlas de Mercado

Canada's GDP Revisions Mean Lower Debt-to-GDP Ratio, Better Productivity -- Market Talk

1 dic 2025, 21:17 UTC

Adquisiciones, fusiones, absorciones

Commercial Metals Expects to Close Foley Products Deal by End of 2025 >CMC

1 dic 2025, 21:17 UTC

Adquisiciones, fusiones, absorciones

Commercial Metals Completes Acquisition of Concrete Pipe & Precast for $675M Cash >CMC

1 dic 2025, 21:15 UTC

Adquisiciones, fusiones, absorciones

Commercial Metals Completes Acquisition Of Concrete Pipe & Precast, LLC >CMC

1 dic 2025, 20:15 UTC

Charlas de Mercado

Natural Gas Turns Positive Amid Mixed Weather Trends -- Market Talk

1 dic 2025, 20:00 UTC

Adquisiciones, fusiones, absorciones

Marsh McLennan Agency Acquires Three Hawai'i-based Insurance Brokerages >MMC

1 dic 2025, 18:54 UTC

Charlas de Mercado

Silver Hits New Record As Momentum Continues -- Market Talk

1 dic 2025, 18:46 UTC

Charlas de Mercado

Luxury Seen With Accelerating Growth Next Year -- Market Talk

1 dic 2025, 16:41 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

1 dic 2025, 16:41 UTC

Charlas de Mercado

Rapid Wage Growth in Canada to Keep BOC Sidelined -- Market Talk

1 dic 2025, 16:20 UTC

Charlas de Mercado

Yen Could Strengthen Further Against Dollar on Rate-Hike Prospects -- Market Talk

1 dic 2025, 16:00 UTC

Ganancias

Strategy Helped Solve Its Bitcoin-Preferred Problem. Here's How. -- Barrons.com

1 dic 2025, 15:51 UTC

Adquisiciones, fusiones, absorciones

Goldman Makes a $2 Billion Bet on 'Boomer Candy' -- WSJ

1 dic 2025, 15:47 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

1 dic 2025, 15:47 UTC

Charlas de Mercado

Airbus Guidance Is at Risk -- Market Talk

1 dic 2025, 15:46 UTC

Adquisiciones, fusiones, absorciones

Synopsys Gets a New Investor. What to Know About Nvidia's Stake. -- Barrons.com

1 dic 2025, 15:33 UTC

Charlas de Mercado

Airbus Selloff May Be Overdone -- Market Talk

1 dic 2025, 15:26 UTC

Charlas de Mercado

Warming Forecast Pressures Natural Gas -- Market Talk

1 dic 2025, 15:23 UTC

Charlas de Mercado

Geopolitical Turmoil Supports Crude Oil -- Market Talk

1 dic 2025, 14:59 UTC

Adquisiciones, fusiones, absorciones

Goldman's Latest Acquisition Is a $2 Billion Bet on Active ETFs -- Barrons.com

Comparación entre iguales

Cambio de precio

Cassava Sciences Inc previsión

Precio Objetivo

By TipRanks

164.03% repunte

Estimación a 12 Meses

Media 8 USD 164.03%

Máximo 8 USD

Mínimo 8 USD

De acuerdo con 1 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Cassava Sciences Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

1 ratings

Comprar

Mantener

Vender

De acuerdo con 1 analistas que ofrecen calificaciones bursátiles a para Cassava Sciences Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

1.56 / 1.7Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentimiento

By Acuity

334 / 374 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Cassava Sciences Inc

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.